VISCHER Ltd advises the investors in the seed financing round of CHF 2.5 million of BioVersys. With this, BioVersys has taken the first step towards the development of novel therapies to overcome bacterial resistance against antibiotics. The team at VISCHER AG is led by Matthias Staehelin (Partner) with Martina Strub (Associate).